Ex­clu­sive: FDA prob­ing death of Aduhelm pa­tient as Bio­gen's Alzheimer's drug con­tin­ues to stir con­tro­ver­sy

The FDA tells End­points News to­day that it’s aware of the death of a pa­tient tak­ing Bio­gen’s con­tro­ver­sial Alzheimer’s drug Aduhelm (ad­u­canum­ab) and is “ac­tive­ly in­ves­ti­gat­ing” the case.

Their state­ment fol­lows the lat­est com­ments from RBC an­a­lyst Bri­an Abra­hams, who is back with an up­date on the death, and this time he says that there are sol­id rea­sons to be­lieve that the event was like­ly drug re­lat­ed and may have been pre­ventable.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER